DiaMedica Therapeutics In...

NASDAQ: DMAC · Real-Time Price · USD
6.03
0.02 (0.33%)
At close: Aug 15, 2025, 3:59 PM
6.03
0.08%
After-hours: Aug 15, 2025, 04:10 PM EDT

DiaMedica Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
13.8M 13.8M 13.8M 30.84M 30.84M 30.84M 30.84M n/a 76K 89K 89K 89K 13K n/a n/a n/a n/a n/a
Cost of Revenue
6.89M 6.9M 6.9M 6.91M 5.18M 9.91M 15.43M 15.43M 13.4M 12.02M 10.03M 10.03M 10.32M 10.32M 10.41M 10.4M 10.3M 9.65M
Gross Profit
7K -3K n/a -6.91M -5.18M -9.91M -15.43M -15.43M -13.32M -11.93M -9.95M -9.95M -10.31M -10.32M -10.41M -10.4M -10.3M -9.65M
Operating Income
-23.45M -29.08M -26.68M -24.11M -27.54M -26.64M -26.42M -24.55M -17.36M -15.99M -14M -13.27M -13.56M -13.56M -13.65M -14.67M -14.57M -13.91M
Interest Income
n/a n/a n/a n/a n/a n/a n/a 353K 353K 353K 388K 35K 35K 35K 4K 4K 4K 4K
Pretax Income
-29.55M -26.97M -24.41M -21.66M -19.86M -19.22M -19.34M -17.94M -16.53M -15.41M -13.65M -13.14M -13.53M -13.45M -13.56M -14.52M -14.27M -13.46M
Net Income
-29.58M -27M -24.44M -21.7M -19.9M -19.26M -19.38M -17.97M -16.56M -15.44M -13.68M -13.17M -13.56M -13.48M -13.59M -14.55M -14.29M -13.49M
Selling & General & Admin
8.52M 8.05M 7.62M 7.84M 7.82M 8.31M 8.15M 7.69M 7.29M 6.5M 6.16M 5.83M 5.43M 5.23M 4.88M 4.65M 4.71M 4.58M
Research & Development
22.93M 21.04M 19.06M 16.26M 14.55M 13.17M 13.11M 11.7M 10.07M 9.48M 7.84M 7.44M 8.13M 8.33M 8.77M 10.01M 9.86M 9.34M
Other Expenses
n/a n/a n/a n/a n/a 271K 527K 527K 603K 345K 124K 131K 28K 113K 82K 75K 205K 285K
Operating Expenses
31.45M 29.08M 26.68M 24.1M 22.38M 21.48M 21.26M 19.39M 17.36M 15.99M 14M 13.27M 13.56M 13.56M 13.65M 14.67M 14.55M 13.82M
Interest Expense
n/a n/a n/a 5.76M 5.76M 5.76M 5.76M 159K 159K 159K 194K 35K 35K 35K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a -8K -8K -8K -8K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
23.45M 29.08M 26.68M 24.11M 22.38M 21.49M 21.27M 19.39M 17.36M 15.99M 14M 13.27M 13.56M 13.56M 13.65M 14.67M 14.55M 13.82M
Income Tax Expense
16K 29K 30K 43K 43K 43K 43K 28K 28K 28K 28K 28K 28K 28K 28K 28K 23K 25K
Shares Outstanding (Basic)
42.96M 42.84M 42.82M 42.75M 38.07M 37.96M 37.96M 37.95M 27.31M 26.45M 26.44M 26.44M 26.44M 26.44M 19.04M 19.04M 18.79M 18.77M
Shares Outstanding (Diluted)
42.96M 42.84M 42.82M 42.75M 38.07M 37.96M 37.96M 37.95M 27.31M 26.45M 26.44M 26.44M 26.44M 26.44M 19.04M 19.04M 18.79M 18.77M
EPS (Basic)
-0.69 -0.64 -0.6 -0.56 -0.53 -0.56 -0.62 -0.62 -0.62 -0.59 -0.52 -0.55 -0.61 -0.65 -0.71 -0.79 -0.8 -0.8
EPS (Diluted)
-0.69 -0.64 -0.6 -0.56 -0.53 -0.56 -0.62 -0.62 -0.62 -0.59 -0.52 -0.55 -0.61 -0.65 -0.71 -0.79 -0.8 -0.8
EBITDA
-23.41M -29.04M -26.64M -24.07M -22.35M -21.46M -21.24M -19.36M -17.34M -15.96M -13.98M -13.25M -13.54M -13.54M -13.62M -14.64M -14.55M -13.89M
EBIT
-23.45M -29.08M -26.68M -24.11M -22.38M -21.49M -21.27M -19.39M -17.36M -15.99M -14M -13.27M -13.56M -13.56M -13.65M -14.67M -14.55M -13.82M
Depreciation & Amortization
32K 42K 39K 36K 34K 48K 64K 62K 61K 43K 25K 25K 24K 24K 24K 23K 22K 21K